|
1. Biologie
|
|
|
|
1.1 Biologie - Gènes
|
|
|
Cancer Genetic Mutations not all Treatable: System to Rank Relevance of Mutations Needed [ESMO]
|
|
|
|
|
|
The
TCGA collaboration conducted genome analysis, called the Pan-Cancer
Atlas, on more than 10,000 tumours from 33 types of cancer and published
29 papers. “The studies highlight genomic alterations in cancer tissue,
but while it is tempting to believe that they are all important,
sometimes giving a drug matched to the mutation does not benefit
patients,” said Prof. Fabrice André.
|
|
|
|
|
|
|
3.1.1 Prévention - Tabac - e-cigs
|
|
|
|
4. Dépistage, diagnostic et pronostic
|
|
|
|
5. Traitements
|
|
|
|
5.1 Traitements - Pré-clinique
|
|
|
|
|
5.12 Immunothérapies
|
|
|
|
5.12.2 Immunothérapies - CAR-T
|
|
|
|
5.12.3 Immunothérapies-combinaisons
|
|
|
With New Data, Drug Combos, Lung Cancer Experts Scramble to Keep Pace [Xconomy]
|
|
|
|
|
|
With
tumor mutation burden now coming to light as an important diagnostic
measurement, for instance, lung cancer is becoming ever more stratified.
Chae is looking forward to each study’s analysis of patient subgroups,
not just the overall numbers. “It will truly be a personalized approach
with this many options coming aboard,” he says.
|
|
|
|
|
|
|
5.12.4 Immunothérapies - Essais
|
|
|
|
|
5.12.7 Immunothérapies - vaccins
|
|
|
|
5.2.1 Pharma - Partenariats
|
|
|
Molecular Partners gets AZ support for lung cancer trial [FierceBiotech]
|
|
|
|
|
|
AZ’s
involvement thus far is simply to supply EGFR inhibitor Tagrisso
(osimertinib) at no charge for the study, but Molecular Partners’ shares
blipped upwards on the announcement on hopes that its drug could
benefit from a positive trial in tandem with AZ’s rapidly growing drug
which was well on its way towards blockbuster status last year with
sales of $955 million.
|
|
|
|
|
|
|
5.3 Traitements - FDA, EMA, NICE...
|
|
|
|
5.6.4 ESMO - Poumon
|
|
|
|
|
5.9.8 AACR - Pharma
|
|
|
|
6.1 Observation
|
|
|
|
6.5 Médecines alternatives
|
|
|
|
6.6 Publications
|
|
|
French Scientists Petition for Firm Stance Against Springer [The Scientist]
|
|
|
|
|
|
A
group of researchers at the French National Center for Scientific
Research (CNRS) started an online petition last weekend (April 8) to
publically support Couperin.org, a national consortium representing more
than 250 academic institutions in France, in its fee negotiations with
academic publisher SpringerNature. More than 2,000 people have signed
the petition so far.
|
|
|
|
|
|
|
6.9 Controverses
|
|
|